Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position
July 11 2022 - 4:30PM
Business Wire
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage
biotechnology company discovering and developing breakthrough
treatments for immune-mediated and oncologic disorders, today
announced the appointment of Nick Mordwinkin, Pharm.D., Ph.D., as
Chief Business Officer. Dr. Mordwinkin will be key to the next
stage of Kezar’s growth and will be responsible for shaping the
company’s business development strategy.
“We are excited to welcome Dr. Mordwinkin to our executive team
as Chief Business Officer. Nick is an experienced leader with a
proven track record of building value through business development
efforts and strategic partnerships,” said John Fowler, Kezar’s
Co-founder and CEO. “As we continue to advance zetomipzomib and
KZR-261 in the clinic and our novel drug discovery platform
targeting the protein secretion pathway, I look forward to working
closely with Nick to drive Kezar’s next chapter of growth.”
“I am thrilled to join Kezar at such a pivotal time for the
company as it continues to advance its pipeline of development
candidates,” said Dr. Mordwinkin. “I look forward to joining a
passionate team that is dedicated to discovering and developing
novel, first-in-class medicines with a patient centric goal of
treating autoimmune diseases and cancer.”
Dr. Mordwinkin joins Kezar with over a decade of experience in
the healthcare industry. Most recently, he served as Head of
Corporate Development, Inflammation and Fibrosis, at Gilead
Sciences, where he led a variety of transactions including
partnerships and out-licensing, as well as a range of corporate
development activities across the entirety of Gilead’s inflammation
franchise. Prior to that, Dr. Mordwinkin served as Senior Director
and Head of Corporate Strategy at Ultragenyx Pharmaceutical, where
he was instrumental in crafting a partnership with GeneTx
Biotherapeutics in 2020 and the acquisition of Dimension
Therapeutics in 2017. Dr. Mordwinkin previously co-founded and
served as the President of Curium Inc., a consulting firm focused
on biotech and pharmaceutical strategy. Before that, he was an
equity research associate at BMO Capital Markets covering SMID-cap
biotechnology companies. Dr. Mordwinkin holds a B.S. in Biology and
Pharm.D. from Nova Southeastern University and a Ph.D. in
Pharmaceutical Sciences from the University of Southern California.
Dr. Mordwinkin completed his postdoctoral training at Stanford
University School of Medicine.
In addition, Kezar is reporting an unaudited cash position of
approximately $307 million, including cash, cash equivalents and
marketable securities as of June 30, 2022.
About Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biopharmaceutical
company discovering and developing breakthrough treatments for
immune-mediated and oncologic disorders. The company is pioneering
first-in-class, small-molecule therapies that harness master
regulators of cellular function to inhibit multiple drivers of
disease via single, powerful targets. Zetomipzomib, its lead
development asset, is a selective immunoproteasome inhibitor being
evaluated in a Phase 2 clinical trial in lupus nephritis. This
product candidate also has the potential to address multiple
chronic immune-mediated diseases. KZR-261 is the first anti-cancer
clinical candidate from the company’s platform targeting the Sec61
translocon and the protein secretion pathway. An open-label
dose-escalation Phase 1 clinical trial of KZR-261 to assess safety,
tolerability and preliminary tumor activity in solid tumors is
underway. For more information, visit
www.kezarlifesciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220711005095/en/
Investor Contact
Gitanjali Jain Vice President, Investor Relations and External
Affairs 650-269-7523 gjain@kezarbio.com
Media Contact
Liza Sullivan Argot Partners 212-600-1902
kezar@argotpartners.com
Kezar Life Sciences (NASDAQ:KZR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kezar Life Sciences (NASDAQ:KZR)
Historical Stock Chart
From Apr 2023 to Apr 2024